This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tilleul, P. Articles by Ozier, Y. Search for Related Content PubMed PubMed Citation Articles by Tilleul, P. Articles by Ozier, Y. Social Bookmarking                   What's this?

Estimated Annual Costs of Prophylaxis and Treatment of Venous Thromboembolic Events Associated With Major Orthopedic Surgery in France

Pharmacie, Hôpital Saint Antoine, Paris

Antoine LaFuma, MD

Service d’Anesthésie, Hôpital Cochin, Paris, antoine.lafuma{at}cemka.fr

Xavier Colin, MSc

Service d’Anesthésie, Hôpital Cochin, Paris

Yves Ozier, MD, PhD

Cemka Eval, Bourg la Reine, France

Venous Thromboembolism (VTE) remains a major complication following orthopedic surgery despite heparin prophylaxis. Clinical consequences associated with this complication are deep vein thrombosis (DVT), pulmonary embolism, and long-term consequences of DVT, especially Postthrombotic syndrome (PTS). The purpose of the present study was to estimate the annual direct costs of VTE following major orthopedic surgery of the lower limb in France. This cost of illness study was performed by using available information from health system databases (1999) and literature and specific surveys (2002). Direct costs were calculated by using estimates of the number of patients with major orthopedic surgery in France during one year. Patients presenting with VTE were identified from the national disease-related group inpatient database. Additional resource consumption was identified by comparison with disease-related groups without the VTE complications. Ambulatory care costs after hospitalization, for recurrences and PTS, were estimated from specific surveys of general practitioners and venous disease specialists. Total annual costs of VTE associated with major orthopedic surgery for the French Sickness Fund were estimated to be approximately 60 million euros over 1 year with 28 million euros for inpatient care and 30 million euros for recurrences and PTS.

Key Words: Costs • Thromboembolic events • France • Prophylaxis • Major orthopedic surgery

References

• Douketis J, Eikelboom J, Quinlan D, et al. The epidemiology of venous thromboembolism after hip and knee arthroplasty surgery. Abstract No. P2213, XVIII Congress The International Society on Thrombosis and Haemostasis July 6-12, 2001, Paris, France.Thromb Haemost July 2001 (Suppl.).
• International Consensus Statement. Prevention of thromboembolism. Int Angiol 1997; 16: 3-3.[ISI][Medline] [Order article via Infotrieve]
• Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-1780.[Abstract]
• Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227-227.[ISI][Medline] [Order article via Infotrieve]
• Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(Suppl. 1): 132S-132S.[Free Full Text]
• De Thomasson E, Strauss C, Girard P, et al. Detection of asymptomatic venous thrombosis after lower limb prosthetic surgery. Retrospective evaluation of a systematic approach using Doppler ultrasonography: 400 cases. Presse Med 2000; 29(7): 351-351.[ISI][Medline] [Order article via Infotrieve]
• Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. Thromb Haemost 1998; 79: 902-902.[ISI][Medline] [Order article via Infotrieve]
• Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg 1995; 77 B6-B6.
• Trowbridge A, Boese CK, Woodruff B, et al. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty: A pilot study. Clin Orthop 1994; 299: 203-203.
• Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126(6): 454-454.[Abstract/Free Full Text]
• Bartolo M. Socioeconomic impact of venous diseases in Italy. Phlebologie 1992; 45(4): 423-423.[Medline] [Order article via Infotrieve]
• Wienert V. The epidemiology and socio-economics of venous diseases in Germany. Phlebologie 1993; 46(2): 225-225.[Medline] [Order article via Infotrieve]
• Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 1998; 3(1): 57-57.[Abstract/Free Full Text]
• Ginsberg JS, Turkstra F, Buller HR, et al. Postthrombotic syndrome after hip or knee arthroplasty: A cross-sectional study. Arch Intern Med 2000; 160(5): 669-669.[Abstract/Free Full Text]
• Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003; 21(7): 477-477.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6(1): 59-59.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002; 59(18): 1750-1750.[Abstract/Free Full Text]
• Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics. Am J Health Syst Pharm 2001; 58(Suppl. 2): S4-S4.[Abstract/Free Full Text]
• Calculation from the "National Costs Database" 1999. Paris, France: Ministère de la Santé.
• Kahn SR, Ducruet T, Johri M, et al. The economic burden of deep venous thrombosis during the first 4 months following diagnosis: A prospective evaluation. Oral presentation, American Society of Hematology Annual Meeting, San Diego, Dec 2003.Blood 2003; 11:Abstract No. 710.
• Benard E, Priollet P, Delecroix M. Prise en charge hospitalière et ambulatoire de la maladie veineuse thromboembolique en France: Un état des lieux. J Mal Vasc 2004; 29(3): 139-139.[ISI][Medline] [Order article via Infotrieve]
• Detournay B, Planes A, Vochelle N, et al. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998; 13: 81-81.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Heit JA. Low-molecular-weight heparin: The optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res 2001; 101(1): V163-V163.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158(14): 1525-1525.[Abstract/Free Full Text]
• Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 2000; 160(6): 769-769.[Abstract/Free Full Text]
• Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348(9022): 224-224.[CrossRef][ISI][Medline] [Order article via Infotrieve]
• Kolbach DN, Neumann HA, Prins MH. Definition of the post-thrombotic syndrome, differences between existing classifications. Eur J Vasc Endovasc Surg 2005; 4: 404-404.[CrossRef]
• IMS-DOREMA Diagnostics, Printemps 2001, Paris.
• Echelle nationale des coûts privés (1999). Paris: ADIMEHP.
• Echelle nationale des coûts publics (1999). Paris: DHOS, Ministère de la Santé.
• Nomenclature Générale des Actes Médicaux, Editeur Union des Caisses Nationales de Sécurité Sociale, 2001 Paris.
• Tarifs Interministériel des Prestations Sanitaires, Editeur UCANSS, 2001 Paris.
• Dictionnaire Vidal. Editions Vidal, 2001, Paris.
• Cago A, Lensing AW, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Arch Intern Med 1993; 153: 2777-2777.[Abstract]
• Markel A, Manzo RA, Bergelin RO, et al. Pattern and distribution of thrombi in acute venous thrombosis. Arch Surg 1992; 127: 305-305.[Abstract]
• Drouet L. Low molecular weight heparins. Presse Med 1993; 22(40): 2002-2002.[ISI][Medline] [Order article via Infotrieve]

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tilleul, P. Articles by Ozier, Y. Search for Related Content PubMed PubMed Citation Articles by Tilleul, P. Articles by Ozier, Y. Social Bookmarking                   What's this?